The November 9, 2026 NAION communication is the immediate review item. FDA requires application holders to add information about a potential increased risk of this rare but serious eye condition to GLP-1 warnings and precautions. FDA advises clinicians to instruct patients to report sudden visual disturbances immediately and promptly refer suspected cases to an ophthalmologist. Decisions about continuing therapy belong to the treating clinician. FDA NAION communication. (fda.gov)
Earlier, on January 13, 2026, FDA requested removal of suicidal-behaviour/ideation warning language from Saxenda, Wegovy and Zepbound after its review found no increased risk. That communication still advises reporting new or worsening depression or unusual mood changes. FDA January communication. (fda.gov)
Buyer action: require version-controlled counselling, patient-support scripts and medication information. Ask each partner who monitors label changes, approves revised content and notifies the clinic. Do not assume a regulatory announcement means every downstream document has already been updated.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential?trk=public_post_comment-text
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp